Antiallodynic Effect of Herbal Medicine Yokukansan on Peripheral Neuropathy in Rats with Chronic Constriction Injury by Suzuki, Yasuyuki et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 953459, 8 pages
doi:10.1155/2012/953459
Research Article
AntiallodynicEffectof Herbal MedicineYokukansan on
PeripheralNeuropathy in Rats with Chronic Constriction Injury
YasuyukiSuzuki,1 HiromasaMitsuhata,2 Mitsutoshi Yuzurihara,1 andYoshioKase1
1Tsumura Research Laboratory, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
2Department of Anesthesiology and Pain Medicine, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinsuna,
Koto-ku, Tokyo 136-0075, Japan
Correspondence should be addressed to Yasuyuki Suzuki, suzuki yasuyuki@mail.tsumura.co.jp
Received 16 June 2011; Accepted 2 November 2011
Academic Editor: Alvin J. Beitz
Copyright © 2012 Yasuyuki Suzuki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Yokukansan, one of the traditional Japanese herbal medicines, ameliorated neuropathic pain symptoms in patients. In this study,
we investigated the eﬀects of yokukansan on neuropathic pain in chronic constriction injury (CCI) model. Oral administration of
yokukansan signiﬁcantly inhibited mechanical and cold allodynia in the von Frey hair or acetone test, respectively. In comparison,
amitriptyline, a tricyclic antidepressant, demonstrated moderate, but not signiﬁcant, antiallodynic eﬀects in the mechanical
and cold tests. Yokukansan signiﬁcantly inhibited the cerebrospinal ﬂuid dialysate level of glutamate that had increased by
the stimulation of brush or acetone. Glutamate transporter inhibitors, DL-threo-beta-hydroxy aspartate and dihydrokainate,
decreased the yokukansan-induced antiallodynic actions in CCI rats. Our results suggest that yokukansan was conﬁrmed to have
antiallodynic eﬀects in CCI rats, which are related to a blockade of glutamatergic neurotransmission via activation of glutamate
transporters in the spinal cord.
1.Introduction
Chronic pain related to peripheral neuropathy is clinically
important.Neuropathicpainisoftencharacterizedbypatho-
logical symptoms such as hyperalgesia and allodynia, as also
reported for spontaneous pain [1, 2]. Mechanical or cold
allodynia is a problem that depreciates the quality of life of
patients. For the treatment of neuropathic pain, opioid anal-
gesics,tricyclicantidepressants,anticonvulsiveagentssuchas
gabapentin, and topical anesthetics have been administered,
and nonpharmacological treatments including acupuncture
and electrical stimulation have been performed. However,
they are not completely eﬀective in ameliorating neuropathic
pain, thus new treatments and drugs are necessary [3, 4].
Yokukansan is one of the traditional Japanese medicines
called kampo in Japan. It is composed of seven kinds of
medicinal herbs. Yokukansan has been approved by the
Ministry of Health, Labor, and Welfare of Japan as a reme-
dy for neurosis, insomnia, and irritability in children. Re-
cently, yokukansan was reported to improve behavioral and
psychological symptoms of dementia (BPSD) including hal-
lucinations, agitation, and aggressiveness in patients with
Alzheimer’s disease, dementia with Lewy bodies, and other
forms of senile dementia [5, 6]. We previously found that
yokukansan clinically attenuates neuropathic pain due to
postherpetic neuralgia, complex regional pain syndrome,
and central cord syndrome and reported that yokukansan
ameliorates neuropathic pain symptoms in patients [7].
Animal models of peripheral nerve injury are useful to
elucidate the mechanisms underlying neuropathic pain [8]
and to improve current clinical treatments [9]. Chronic con-
striction injury (CCI), an animal model of neuropathic pain
proposed by Bennett and Xie [10], produces pronounced
behavioral responses and it can reproduce signs noticed in
humans, contributing thereby to advance the understanding
of neural mechanisms in neuropathic pain disorders [8].
The Bennett and Xie model is commonly used for studies
of mononeuropathy characterized by the mechanical and
cold allodynia that are produced by chronic constriction of
the sciatic nerve. We evaluated the eﬀects of yokukansan on2 Evidence-Based Complementary and Alternative Medicine
allodynia using rats with CCI-induced neuropathy in this
study.
2. Methods
2.1. Animals. Male Sprague-Dawley (SD) rats weighing
250300g (Japan SLC Ltd., Hamamatsu, Japan) were used.
The animals were allowed free access to water and standard
laboratory food (MF, Oriental Yeast, Tokyo, Japan) and kept
in a facility at a temperature of 23 ± 3◦C and relative humid-
ity of 50 ± 20%, with lights on from 07:00 to 19:00 daily. All
experimental procedures were performed according to the
“Guidelines for the care and use of laboratory animals”
approved by the Laboratory Animal Committee of Tsumura
&C o .
2.2. Drugs. Yokukansan, which is manufactured by Tsumura
& Co. (Tokyo, Japan) and approved for ethical use by the
Ministry of Health, Labor, and Welfare of Japan, is a dried
extract of the following botanical raw materials: 4.0 parts
Atractylodis Lanceae Rhizoma (rhizome of Atractylodes lan-
cea De Candolle, Compositae), 4.0 parts Poria (sclerotium
of Poria cocos Wolf, Polyporaceae), 3.0 parts Cnidii Rhizoma
(rhizome of Cnidium oﬃcinale Makino, Umbelliferae), 3.0
parts Angelicae Radix (root of Angelica acutiloba Kitagawa,
Umbelliferae), 2.0 parts Bupleuri Radix (root of Bupleurum
falcatum Linn´ e, Umbelliferae), 1.5 parts Glycyrrhizae Radix
(root and stolon of Glycyrrhiza uralensis Fisher, Legumi-
nosae), and 3.0 parts Uncaria Uncis Cum Ramulus (hook
of Uncaria rhynchophilla Miquel, Rubiaceae). Each plant
component was identiﬁed by its external morphology and
authenticated by marker compounds of plant specimens
according to the methods of the Japanese Pharmacopoeia
and our company’s standards. The seven medical herbs were
extracted with puriﬁed water at 95◦C for 1h, and the extract
solution was separated from the insoluble waste and con-
centrated by removing water under reduced pressure. Spray
drying was used to produce a dried extract powder. The yield
of the extract was about 15.9%.
Yokukansan and amitriptyline hydrochloride, which was
purchased from Wako Chemicals Industries (Osaka, Japan),
were dissolved in distilled water and administered by oral
gavage. DL-threo-beta-hydroxyaspartate (TBHA, Sigma-
Aldrich, St. Louis, MO, USA) was dissolved in phosphate-
buﬀered saline containing 1% dimethyl sulfoxide, and dihy-
drokainate (DHK, Sigma-Aldrich) was dissolved in PBS.
2.3. Chronic Constriction Injury. The chronic constriction
injury(CCI)wasproducedasdescribedpreviously[10].Rats
were anesthetized with sodium pentobarbital (50mg/kg,
i.p.), and the right common sciatic nerve was exposed at the
level of the middle of the thigh by blunt dissection through
the biceps femoris muscle. Four ligatures (4–0 monocryl
monoﬁlament), about 1mm apart, were tied loosely around
the nerve. The muscle layer and skin layer were closed using
silk thread. In sham-operated rats, the right sciatic nerve was
exposed but not ligated.
2.4. Mechanical Allodynia. The responsiveness to innocuous
mechanicalstimulationwasdeterminedbyprobingthelater-
al edge of the plantar hind paw surface with an ascending
series of von Frey ﬁlaments (1.4–60g, North Coast Medical,
Inc., Morgan Hill, CA, USA). Rats were placed in a metal
mesh cage raised 20cm above the ﬂoor, and the animals
were allowed to adapt for approximately 20min or until
exploratory behavior ceased. Lifting of the paw due to nor-
mal locomotor behavior was ignored. Starting with the
smallest force, the von Frey ﬁlament was placed on the skin
until it bowed slightly, with each ﬁlament presented ﬁve
t i m e sa tar a t eo fa b o u t1 / s .Ad i ﬀerent region within the
test area was stimulated with each presentation. If a with-
drawal response was not elicited, the next ascending von
Frey ﬁlament was applied until a response occurred. The
minimum force-reproducible ﬂexion-withdrawal reﬂex on
ﬁve applications of von Frey hairs to the right hind paw
was measured as the mechanical withdrawal threshold. The
antiallodynic activity was evaluated every 1h for 4h after
administration of the drugsl.
2.5. Cold Allodynia. For the assessment of cold allodynia, the
rats were placed in a metal mesh cage and allowed to habitu-
ate for approximately 20min or until exploratory behavior
ceased. Cold allodynia was measured by squirting 250μL
of acetone onto the midplantar surface of the hind paw as
described by Choi et al. [11]. A positive response to acetone
was deﬁned as a sharp withdrawal of the hind paw lasting
>1s.Verybriefwithdrawalslasting<1swereassignedavalue
of 0 because they could be occasionally induced by acetone
but were never observed after the application of water. The
paw elevation time was measured for 1min with a digital
stopwatch from the onset of the paw withdrawal until the
paw was rested again on the cage ﬂoor for at least 2s. The
antiallodynic activity was evaluated every 1h for 4h after
administration of the drugs.
2.6. Intrathecal Catheters. Intrathecal catheters were im-
planted in rats according to the method of Yamamoto and
Yaksh [12] with minor modiﬁcations. Brieﬂy, the atlanto-
occipital membrane was incised right below the skull, and
a PE-10 polyethylene catheter ﬁlled with sterile saline was
introduced 9cm into the spinal cavity so that the catheter tip
extended to the rostal edge of the lumbar enlargement. The
catheter was externalized on the top of the skull and sealed
with a piece of steel wire and the wound closed with 3–0
silk sutures. After a one-week recovery period, animals with
normal neurologic function were operated the CCI surgery.
2.7. In Vivo Microdialysis. CCI rats under sodium pentobar-
bital (50mg/kg, i.p.) anesthesia were implanted with a single
dialysis catheter (Marsil Scientiﬁc, San Diego, CA) into the
subarachnoid space through an incision between the L4–L5
vertebrae.Thetotallengthofthecatheterwas9cm,including
anactivedialysisﬁberlengthof4cm(0.2mminnerdiameter,
0.3mm outer diameter, 11kDa cut-oﬀ) .T h ea c t i v es i t ew a s
positioned to span lumbar enlargement segments. The dialy-
sisﬁberwasconnectedtotheouterlumenofthepolyethyleneEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of yokukansan on mechanical (a) and cold (b) allodynia in CCI-induced neuropathic rats. Yokukansan (0.3, 1.0g/kg, p.o.)
or distilled water (DW) was administered orally at time zero. Each point represents the mean ± SEM. ∗P<0.05, ∗∗P<0.01 compared with
the respective distilled water (DW) treatment group.
tubing via 1cm length of fused silica tubing used as stents,
with methacrylate adhesive on the outside. Fine gauge wire
lengthwise inside the dialysis ﬁber prevented crimping. The
two distal ends of the catheter were tunneled subcutaneously
and externalized through the skin in the neck region and
plugged with short wire. The experiments were performed at
least ﬁve days after the implantation of the dialysis catheter.
Only rats with normal behavior and no paralysis of the hind
limbs after the surgery were included in the microdialysis
studies. The rats were used only once for the experiments.
After recovery from surgery, microdialysis experiments were
carried out with unanesthetized and freely moving animals
placedinaPlexiglaschamber(30cmwide,40cmlong,40cm
high). The dialysis catheter was perfused with artiﬁcial cere-
brospinal ﬂuid (ACSF; 147mM NaCl, 4.0mM KCl, 2.3mM
CaCl2,pH6.4)ataconstantﬂowrateof2μL/min.Methylene
blue dye was perfused through the dialysis probe to verify
the position of the dialysis ﬁber. The samples were collected
a s2 0 m i nf r a c t i o n sa n df r o z e na t−80◦C until analysis.
Three consecutive samples were collected for determination
of basal levels after an initial washout period of 60min,
and then rats received oral administration of yokukansan
(1g/kg) or distilled water (10mL/kg). One hour after oral
administration, touch stimulation of the aﬀected leg with
a brush or cold stimulation with 0.25mL of acetone was
performed every minute for 20 minutes. The glutamate level
in the perfusate was determined by a high-performance liq-
uid chromatography system with electrochemical detection
witho-phthalaldehydederivatization.Thederivatizationwas
carried out by mixing 30μL of perfusate and 10μLo f4m M
o-phthalaldehyde-2-mercaptoethanol at 10◦C for 10min.
The chromatographic conditions were column: EICOMPAK
SC-5ODS (3.0Φ × 150mm long, Eicom), mobile phase:
0.1M phosphate buﬀer, pH 6.0, containing 29% methanol
and 13.4m M EDTA-2Na, ﬂow rate: 0.5mL/min, column
temperature: 30◦C, an applied potential to an Ag/AgCl ref-
erence electrode: +600mV, and working electrode: graphite
electrode.
2.8. Statistical Analysis. The results are expressed as means ±
SEM. Signiﬁcance was determined using one-way analysis of
variance (ANOVA), followed by Dunnett’s t-test or two-way
ANOVA. In all cases, diﬀerences of P<0.05 were considered
signiﬁcant.
3. Results
InthemechanicalallodyniatestusingvonFreyﬁlaments,the
withdrawal threshold before drug administration in the CCI
group (7.8g ± 1.3, N = 10) was lower than in the Sham
group(46.4g ±8.3, N = 5),suggestingmechanicalallodynia
(P<0.01, Student’s t-test). When yokukansan at a dose of
1.0g/kgwasorallyadministered,mechanicalhypersensitivity
in response to von Frey hair stimulation was signiﬁcantly
attenuated (Figure 1(a)). In the cold allodynia test with
acetone stimulation, the duration of withdrawal responses
before drug administration in the CCI group (27.0 ± 2.6sec,
N = 10) was longer than in the Sham group (3.3 ± 1.4sec,
N = 5), suggesting cold allodynia (P<0.01, Student’s t-
test). Cold allodynia of the injured hind paw was also dose
dependently reduced by administration of yokukansan (0.3,
1.0g/kg,p.o.)whencomparedwiththecontrol(Figure 1(b)).
Oraladministrationofamitriptyline(20,60mg/kg)hadlittle
eﬀect on mechanical or cold hypersensitivity in response to
vonFreyhairoracetonedropstimulationoftheinjuredhind
paw compared with the controls (Figures 2(a) and 2(b)).
These diﬀerences were not statistically signiﬁcant.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀects of amitriptyline on mechanical (a) and cold (b) allodynia in CCI-induced neuropathic rats. Amitriptyline (20, 60mg/kg,
p.o.) or distilled water (DW) was administered orally at time zero. Each point represents the mean ± SEM.
In CCI rats, mechanical stimulation with a brush tran-
siently increased the level of glutamate in the spinal cord
measured by microdialysis analysis. Oral administration of
yokukansan at 1.0g/kg inhibited the elevation of glutamate
level in the spinal cord between 60 and 180 minutes after
administration, during which signiﬁcant actions were ob-
served in the mechanical allodynia test (P<0.01, two-way
variance analysis; Figure 3(a)). Furthermore, cold stimula-
tion with acetone also increased the level of glutamate in
spinalcordofCCIrats.Oraladministrationofyokukansanat
1g/kg inhibited the elevation of glutamate in the spinal cord
between 60 and 120 minutes after administration, during
which signiﬁcant eﬀects were obtained in the cold allodynia
test (P<0.05, two-way variance analysis; Figure 3(b)).
In the preliminary microdialysis study, we examined
spinal cord glutamate release induced by intrathecal (i.t.)
injections of TBHA (1, 3, 10μg) or DHK (5, 10, 20mM). As
a result, the intrathecal injections of TBHA (1μg) and DHK
(5mM) did not increase intraspinal glutamate by themselves
(data not shown). Therefore we used 1μgo fT B H Aa n d
5mM of DHK for the behavioral tests. The comparison of
measurements on each test one hour after yokukansan ad-
ministration with the pretreatment values is shown in
Figure 4. In the mechanical allodynia test, the intrathecal
administration of TBHA (1μg), which nonspeciﬁcally inhib-
its glutamate transporter-1 (GLT-1) and glutamate-aspartate
transporter (GLAST), or DHK (5mM), a GLT-1-selective
inhibitor, signiﬁcantly reduced the antiallodynia actions of
yokukansan at 1g/kg (Figure 4(a)). In the cold allodynia
test, TBHA (1μg, i.t.) signiﬁcantly reduced the antiallodynia
actions of yokukansan at 1g/kg. DHK (5mM, i.t.) inhibited
the actions of yokukansan, although there was no signiﬁcant
diﬀerence (Figure 4(b)).
4. Discussion
Recently we found that yokukansan clinically improves sub-
jective symptoms of neuropathic pain [7]. In the present
study, we demonstrated that administration of yokukansan
produced antiallodynic eﬀects against mechanical and cold
stimuli in the painful peripheral neuropathy rat model with
CCI, implying that this antiallodynic eﬀect may be one of the
factors that attenuate neuropathic pain in patients.
Tricyclic antidepressants, including amitriptyline, are
currently used for neuropathic pain. Amitriptyline is rec-
ommended as ﬁrst-line treatment in painful neuropathy in
some clinical guidelines including European Federation of
Neurological Societies and National Institute for Health and
Clinical Excellence [3, 13]. We used amitriptyline in this
experiment to conﬁrm eﬀect of amitriptyline in CCI model
rat.Tricyclicantidepressantsareconsideredeﬀectiveforboth
steady and lancinating or brief pains, whereas it is more
diﬃculttojudgeifthesedrugsalsorelievetouch-evokedpain
[2]. When amitriptyline was administered orally to rats with
peripheral nerve injury in this study, mechanical allodynia
was only slightly attenuated. This result is consistent with
reports that amitriptyline is not eﬀective in mechanical
allodynia in CCI models or spinal ligation models [14–
16]. Similarly, amitriptyline (60mg/kg, p.o.) tended to have
little eﬀect on cold allodynia, and its eﬀects were not
statistically signiﬁcant in CCI rats. This result is consistent
with a previous report by Wang et al. [16]. Collectively,
these ﬁndings suggest that amitriptyline has limited eﬀect
on neuropathic pain. In contrast, yokukansan markedly
improved allodynia in the same models.
Theresultsofthisstudyshowedthatmechanicalstimula-
tion with a brush or cold stimulation with acetone increased
the glutamate level in the dialysate obtained from the spinalEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of mechanical (a) or cold (b) stimulation on the levels of lumbar segment enlargement of glutamate in CCI rats and the
eﬀects of yokukansan. The time of oral yokukansan (1.0g/kg) or distilled water (control) administration was regarded as minute 0. Mean ±
standard error, ∗P<0.05, ∗∗P<0.01 versus control group (two-way ANOVA).
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Figure 4: Eﬀect of glutamate transporter inhibitors on the anti-allodynic eﬀects of yokukansan on mechanical (a) or cold (b) stimulation
with a von Frey ﬁlament or acetone in CCI rats. A glutamate transporter inhibitor, TBHA (1μg) or DHK (5mM), was simultaneously
intrathecally injected when yokukansan (1.0g/kg) was orally administered. Diﬀerences between values before and 1 hour after yokukansan
administration are expressed as the mean ± standard error. ∗P<0.05, ∗∗P<0.01 versus yokukansan alone (Dunnett’s t-test).
cordofCCIrats.Oraladministrationofyokukansanat1g/kg
inhibited such an increase in the dialysate glutamate level
related to these stimuli.
The amino acid glutamate is the major excitatory neu-
rotransmitter in the central nervous system [17]. It is well
known that the spinal glutamatergic system plays an impor-
tant role in physiological nociceptive transmission and in the
induction of central sensitization, which are associated with
neuronal plasticity underlying pathological pain at the spinal
level. Glutamate release in the spinal dorsal horn is elicited
following peripheral inﬂammation or nerve injury [18–21].
Indeed, the microdialysis study conﬁrmed an increase in
the spinal cord cerebrospinal ﬂuid (CSF) level of glutamate
in a rat neuropathic pain model. In a CCI rat neuropathy
model, an increase in the spinal dialysate level of glutamate
related to the intrathecal injection of substance P was more
marked than sham-operated rats [22]. In a rat neuropathic
pain model prepared using the method of Seltzer, the
glutamate level of dialysate in the dorsal horn of allodynic
animals was higher than that of normal animals [23]. These
studies suggest that glutamate is closely involved in spinal
nociceptive transmission in patients with neuropathic pain6 Evidence-Based Complementary and Alternative Medicine
and that the spinal CSF level of glutamate is an index of pain.
The microdialysis data revealed in this study indicate that a
reduction in the spinal CSF level of glutamate is involved in
the antiallodynic mechanism of yokukansan in CCI rats.
In recent years, an increase in the extracellular level of
glutamate and degeneration of neuronal and astroglial cells
were demonstrated in the brains of thiamine-deﬁcient (TD)
rats, and yokukansan was found to inhibit not only the TD-
induced increase in the extracellular level of glutamate, but
also the degeneration of cerebral neurocytes and astrocytes
in vulnerable brain regions [24]. These previous ﬁndings
support the eﬀects of yokukansan on the spinal cord of neu-
ropathic rats obtained in this study. In the present study, the
intrathecal injection of TBHA (1μg), which nonselectively
inhibits GLT-1/GLAST, and DHK (5mM), a selective GLT-1
inhibitor, signiﬁcantly reduced the eﬀects of yokukansan on
mechanical allodynia. TBHA (1μg, i.t.) signiﬁcantly inhib-
ited the anticold allodynic eﬀects of yokukansan, while DHK
(5mM) only slightly reduced them. These results suggest
that yokukansan exhibits antimechanical allodynic eﬀect
via activation of GLT-1, whereas GLAST activation may be
related to eﬀectofyokukansanoncoldallodynia.Itisunclear
why the eﬀect of DHK on antiallodynic eﬀect of yokukansan
was diﬀerent between the mechanical and cold tests. These
results nonetheless suggest that the antiallodynic eﬀects of
yokukansan shown in the present study are related to a
blockade of glutamatergic neurotransmission via activation
of both glutamate transporters in the spinal cord.
Several studies have suggested that glutamate transport-
ers are involved in the development of hyperalgesia or allo-
dynia associated with neuronal plasticity related to central
sensitization following peripheral inﬂammation and nerve
injury. The increase of glutamate reuptake related to the
intrathecal administration of a glutamate transporter activa-
tor or intraspinal overexpression of glutamate transporters
attenuated hyperalgesia and allodynia in rats with inﬂamma-
tory and neuropathic pain [20, 25]. In contrast, intrathecal
injection of glutamate transporter inhibitors into naive ani-
mals elevated the spinal extracellular glutamate level and
produced spontaneous nociceptive-related behaviors and
hyperalgesia [26–28]. On the other hand, CCI in rats signif-
icantly reduced spinal glutamate transporter uptake with an
associated increase in extracellular glutamate concentration
from spinal microdialysates. Furthermore, Sung et al. [29]
demonstrated that both the expression and uptake activity
of spinal glutamate transporters changed after CCI and
contributed to neuropathic pain behaviors in rats. CCI ini-
tially upregulated glutamate transporters until at least post-
operative day 5, primarily within the ipsilateral spinal cord
dorsal horn, which was followed by glutamate transporter
downregulation when examined on postoperative days 7 and
14 by Western blotting and immunohistochemistry. More-
over, CCI signiﬁcantly reduced glutamate uptake activity of
spinal glutamate transporters when examined on postoper-
ative day 5, and this reduction was prevented by riluzole
(a positive glutamate transporter activity regulator) given
intrathecally twice a day on postoperative days 1–4. Riluzole
consistently attenuated and gradually reversed neuropathic
pain behaviors when a 4-day riluzole treatment was given
on postoperative days 1–4 and 5–8, respectively [29]. These
results indicate that changes in the expression of spinal glu-
tamate transporters and their glutamate uptake activity may
play a critical role in both the induction and maintenance
of neuropathic pain after nerve injury via the regulation of
regionalglutamatehomeostasis,arecentlyelucidatedmecha-
nism relevant to the pathogenesis of neuropathic pain.
In comparison, it was demonstrated that yokukansan has
ameliorated TD-induced decreases in the glutamate uptake
function and the levels of GLAST protein and mRNA. This
eﬀect of yokukansan has been linked to its ability to strongly
modulate GLAST [30]. Among the seven constituent herbs
of yokukansan, Glycyrrhiza ameliorated the TD-induced de-
crease in glutamate uptake by astrocytes. Furthermore,
among the eight components of Glycyrrhiza, glycyrrhizin
and its metabolite 18 beta-glycyrrhetinic acid ameliorated
the TD-induced decrease of glutamate uptake in astrocytes.
These two substances have also been found to inhibit protein
kinase C activity under in vitro conditions [31]. Taken
together, these studies provide supporting evidence that the
antiallodyniceﬀectsofyokukansan,asobservedinthisstudy,
are associated with the promotion of glutamate reuptake via
the activation of glutamate transporters in the spinal cord.
Whether the components responsible for such actions of
yokukansan are indeed glycyrrhizin and its metabolite, 18
beta-glycyrrhetinic acid, requires further investigation. Re-
cently, Egashira et al. [32] reported that yokukansan en-
hances the pentobarbital-induced sleep in socially isolated
mice and that the GABAA-benzodiazepine receptor complex
is involved in the eﬀect of yokukansan. Therefore, the partic-
ipationofGABAergicsystemintheantiallodynicmechanism
of yokukansan also should be examined in the future.
In conclusion, yokukansan showed signiﬁcant antiallo-
dynic eﬀect in CCI model rats and, therefore, may be useful
in the treatment of neuropathic pain. The antiallodynic
eﬀects of yokukansan are related to a blockade of glutama-
tergic neurotransmission via activation of glutamate trans-
porters in the spinal cord.
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